home / stock / cslly / cslly quote
Last: | $101.20 |
---|---|
Change Percent: | -1.33% |
Open: | $101.51 |
Close: | $101.20 |
High: | $102.1 |
Low: | $101.03 |
Volume: | 22,487 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$101.2 | $101.51 | $101.2 | $102.1 | $101.03 | 22,487 | 07-05-2024 |
$100.18 | $99.305 | $100.18 | $100.28 | $99.27 | 17,216 | 07-04-2024 |
$100.18 | $99.305 | $100.18 | $100.28 | $99.27 | 17,216 | 07-03-2024 |
$97.6 | $97.6 | $97.6 | $97.78 | $97.3 | 28,882 | 07-02-2024 |
$97.57 | $99.51 | $97.57 | $99.51 | $95.76 | 20,052 | 07-01-2024 |
$98.5 | $99.51 | $98.5 | $99.51 | $98.24 | 20,590 | 06-28-2024 |
$98.62 | $97.36 | $98.62 | $98.62 | $97 | 19,741 | 06-27-2024 |
$97.3688 | $98.08 | $97.3688 | $98.53 | $97.33 | 78,748 | 06-26-2024 |
$97.86 | $95.8 | $97.86 | $98.14 | $95.8 | 38,241 | 06-25-2024 |
$97.97 | $97.56 | $97.97 | $98.17 | $97.56 | 24,963 | 06-24-2024 |
$97.57 | $99.41 | $97.57 | $99.41 | $97.0563 | 29,476 | 06-21-2024 |
$97.09 | $99 | $97.09 | $99.51 | $96.82 | 34,439 | 06-20-2024 |
$97.53 | $95 | $97.53 | $97.86 | $95 | 37,057 | 06-19-2024 |
$97.53 | $95 | $97.53 | $97.86 | $95 | 37,057 | 06-18-2024 |
$96.02 | $95.13 | $96.02 | $96.02 | $94.97 | 32,230 | 06-17-2024 |
$95.23 | $95.09 | $95.23 | $95.23 | $94.72 | 24,657 | 06-14-2024 |
$95.33 | $97.63 | $95.33 | $97.63 | $95.11 | 38,600 | 06-13-2024 |
$94.78 | $92.56 | $94.78 | $96.12 | $92.56 | 26,135 | 06-12-2024 |
$94.24 | $92.88 | $94.24 | $94.24 | $92.88 | 27,085 | 06-11-2024 |
$95.07 | $94.745 | $95.07 | $95.13 | $94.59 | 24,816 | 06-10-2024 |
News, Short Squeeze, Breakout and More Instantly...
CSL Ltd ADR Company Name:
CSLLY Stock Symbol:
OTCMKTS Market:
CSL Seqirus, a Proud Champion of Pandemic Preparedness, Announces U.S. Government Award in Response to Avian Influenza PR Newswire CSL Seqirus to complete the fill and finish process for pre-pandemic vaccine to support the U.S. government's outbreak and preparedness response...
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine PR Newswire Data follow the approval of the world's first self-amplifying (sa-mRNA) COVID-19 vaccine for adults in Japan. These res...
Recently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent Influenza Vaccine Over Three Seasons PR Newswire A real-world evidence (RWE) study recently published in Open Forum Infectious Diseases (OFID) examined three consecutive U.S. flu seas...